plus 4, Roche Reports Progress in Breast Cancer Treatment - ABC News |
- Roche Reports Progress in Breast Cancer Treatment - ABC News
- Hormone Therapy - Not the Only Reason for Decline in Breast Cancer ... - Med India
- Abraxis Provides Overview of Abraxane Study Results to Be Presented at ... - Phramalive.com
- Turmeric, pepper 'can help keep breast cancer at bay' - Daily News and Analysis
- Founder of the Susan D. Komen Race for the Cure will speak at Michigan ... - UpNorthLive.com
| Roche Reports Progress in Breast Cancer Treatment - ABC News Posted: 09 Dec 2009 09:49 AM PST
ZURICH (Reuters) - Roche Holding AG said on Wednesday three studies on its drugs used to treat early and advanced breast cancer showed good results. The Swiss drugmaker, the world's largest maker of cancer drugs, was due to present the results in coming days at the San Antonio Breast Cancer Symposium. Roche said it would present five-year follow-up data from two studies into the use of Herceptin in early breast cancer which sought to answer questions about the best way of giving patients the treatment. It will also present a study into the use of Avastin as a second-line treatment of advanced breast cancer. Finally, it is also presenting new data from a Phase II study into the use of trastuzumab-DM1 for very advanced breast cancer. (Editing by David Holmes) Copyright 2009 Reuters News Service. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. This content has passed through fivefilters.org.  This posting includes an audio/video/photo media file: Download Now |
| Hormone Therapy - Not the Only Reason for Decline in Breast Cancer ... - Med India Posted: 09 Dec 2009 04:20 AM PST "We found that the change in hormone therapy use only accounted for a decline of about 3 percent, so there's another 4 percent that is being caused by something we do not yet know," said Sprague, a postdoctoral fellow at the University of Wisconsin. Results of this study were presented at the American Association for Cancer Research Frontiers in Cancer Prevention Research Conference, held Dec. 6-9 in Houston. In 1991, the National Institutes of Health established the WHI to address the most common causes of death, disability and deterred quality of life among 15,730 postmenopausal women — cancer, cardiovascular disease and osteoporosis. Results of the WHI demonstrated in 2002 that hormone therapy is linked with an increased risk of breast cancer. Other studies have confirmed this relationship, and many women have stopped taking hormone therapy due to concerns about the potential risk of cancer. At the same time, the incidence of breast cancer has declined, which researchers attribute to the decrease in hormone therapy use. After conducting a thorough literature review of the decline in hormone use and the decline in breast cancer incidence, Sprague and colleagues estimated that 42 percent of the decline in incidence of breast cancer was linked to the cessation of hormone therapy use. Sprague said that additional studies are needed to determine the source of the remaining decline in breast cancer cases. "This does not mean that women should start taking hormones again, but there appear to be additional factors that have contributed to the decline in breast cancer," he said.
Source-Eurekalert This content has passed through fivefilters.org. |
| Abraxis Provides Overview of Abraxane Study Results to Be Presented at ... - Phramalive.com Posted: 08 Dec 2009 11:38 AM PST
LOS ANGELES--(BUSINESS WIRE)--Dec 8, 2009 - Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, today announced that multiple clinical studies of the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) will be presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS), being held in San Antonio, Texas from December 9 to December 13. Clinical results from investigator-sponsored studies will be reported, including an ongoing study evaluating the combination of lapatinib and nab®-paclitaxel for first-line treatment of HER2+ breast cancer. Additional presentations will highlight analyses of cost of care in metastatic breast cancer patients, as well as the correlation between specific genotypes and treatment response rates. ABRAXANE is currently approved in the second-line treatment of metastatic breast cancer and Abraxis continues to study the potential of ABRAXANE in areas of high unmet patient needs. Metastatic breast cancer, also known as stage IV, refers to cancer that has spread to distant organs. In the majority of metastatic breast cancer patients, the metastasis is diagnosed after a cancer has already been treated. However, in about six to ten percent of all breast cancer patients, the cancer has spread to distant organs at the time of the first diagnosis. In the United States, there are 155,000 women and men living with metastatic breast cancer.i Results to be presented at the meeting include: -A Taxane total cost of care analysis: Results of private payor claims data in metastatic breast cancer (Abstract #1076) Poster Presentation 1076; Thursday, December 10, 2009, 5:30 p.m. – 7:30 p.m.; Exhibit Halls A-B -Pilot neoadjuvant trial with combination of lapatinib and nab®-paclitaxel in HER2+ breast cancer (Abstract #1091) Poster Presentation 1091; Thursday, December 10, 2009, 5:30 p.m.-7:30 p.m.; Exhibit Halls A-B -The basal-like, luminal-like, and HER2-like genotype and the 70-gene signatures predictors of response to neoadjuvant chemotherapy (NCT) with docetaxel, doxorubicin, cyclophosphamide (TAC), or AC and nab®-paclitaxel and carboplatin +/- trastuzumab (trast) as part of (NCT) in patients (pts) with stage II-III breast cancer [including inflammatory breast cancer (BC)]. (Abstract #2026) Poster Presentation 2026; Friday, December 11, 2009, 7:00 a.m. - 9:00 a.m., Exhibit Halls A-B About ABRAXANE ABRAXANE® is a solvent-free chemotherapy treatment option for metastatic breast cancer which was developed using Abraxis BioScience's proprietary nab® technology platform. This protein-bound chemotherapy agent combines paclitaxel with albumin, a naturally occurring human protein. By wrapping the albumin around the active drug, ABRAXANE can be administered to patients at higher doses, delivering higher concentrations of paclitaxel to the tumor site than solvent-based paclitaxel. ABRAXANE is currently in various stages of investigation for the treatment of the following cancers: expanded applications for metastatic breast, non-small cell lung, malignant melanoma, pancreatic and gastric. The U.S. Food and Drug Administration approved ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in January 2005 for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. The U.S. Food and Drug Administration granted orphan-drug designation for ABRAXANE for the treatment of pancreatic cancer in September 2009 and stage IIb to IV melanoma in October 2009. For the full prescribing information for ABRAXANE please visit www.abraxane.com. About Abraxis BioScience, Inc. Abraxis BioScience is a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses. The company's portfolio includes the world's first and only protein-bound nanoparticle chemotherapeutic compound (ABRAXANE®), which is based on the company's proprietary tumor targeting technology known as the nab®platform. The first FDA approved product to use this nab®platform, ABRAXANE, was launched in 2005 for the treatment of metastatic breast cancer and is now approved in 38 countries. The company continues to expand the nab®platform through a robust clinical program and deep product pipeline. Abraxis trades on the NASDAQ Global Market under the symbol ABII. For more information about the company and its products, please visit www.abraxisbio.com. i Metastatic Breast Cancer Network, http://www.mbcnetwork.org/page.aspx?nm=mainpage. Accessed November 2009.
Contact: Abraxis BioScience, Inc.
This content has passed through fivefilters.org.  This posting includes an audio/video/photo media file: Download Now |
| Turmeric, pepper 'can help keep breast cancer at bay' - Daily News and Analysis Posted: 08 Dec 2009 12:46 AM PST Washington: Spices like turmeric and pepper contain compounds that have the potential to prevent breast cancer by limiting the growth of stem cells, the small number of cells that fuel a tumour's growth, according to researchers at the University of Michigan. The researchers found that when the dietary compounds curcumin, which is derived from the Indian spice turmeric, and piperine, derived from black peppers, were applied to breast cells in culture, they decreased the number of stem cells without affecting normal differentiated cells. "If we can limit the number of stem cells, we can limit the number of cells with potential to form tumours," said lead author Madhuri Kakarala. Cancer stem cells are the small number of cells within a tumour that fuel the tumour's growth. Current chemotherapies do not work against these cells, which is why cancer recurs and spreads. According to researchers, eliminating the cancer stem cells is the key to controlling cancer. In addition, decreasing the number of normal stem cells and unspecialised cells that can give rise to any type of cell in that organ can decrease the risk of cancer. In the current study, a solution of curcumin and piperine was applied to the cell cultures at the equivalent of about 20 times the potency of what could be consumed through diet. The compounds are available at this potency in a capsule form that could be taken by mouth. The researchers applied a series of tests to the cells, looking at markers for breast stem cells and the effects of curcumin and piperine, both alone and combined, on the stem cell levels. They found that piperine enhanced the effects of curcumin, and that the compounds interrupted the self-renewal process that is the hallmark of cancer-initiating stem cells. Besides, the compounds had no affect on cell differentiation, which is the normal process of cell development. "This shows that these compounds are not toxic to normal breast tissue. Women at high risk of breast cancer right now can choose to take the drugs tamoxifen or raloxifene for prevention, but most women won't take these drugs because there is too much toxicity. The concept that dietary compounds can help is attractive, and curcumin and piperine appear to have very low toxicity," said Kakarala. The study is the first to suggest these dietary compounds could prevent cancer by targeting stem cells. It has been published online in the journal Breast Cancer Research and Treatment. This content has passed through fivefilters.org. This posting includes an audio/video/photo media file: Download Now |
| Founder of the Susan D. Komen Race for the Cure will speak at Michigan ... - UpNorthLive.com Posted: 07 Dec 2009 11:13 PM PST Read more: State, Health, Education, Michigan State University, Msu, University, Komen, Breast Cancer, Medical, Fundraiser This content has passed through fivefilters.org. |
| You are subscribed to email updates from Add Images to any RSS Feed To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google Inc., 20 West Kinzie, Chicago IL USA 60610 | |
No comments:
Post a Comment